112,904 Shares in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Bought by Raymond James Financial Inc.

Raymond James Financial Inc. bought a new position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 112,904 shares of the company's stock, valued at approximately $629,000. Raymond James Financial Inc. owned 0.24% of 4D Molecular Therapeutics at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its stake in shares of 4D Molecular Therapeutics by 3.4% in the 4th quarter. Vanguard Group Inc. now owns 2,860,508 shares of the company's stock valued at $15,933,000 after purchasing an additional 92,791 shares during the period. JPMorgan Chase & Co. grew its position in shares of 4D Molecular Therapeutics by 159.5% during the 4th quarter. JPMorgan Chase & Co. now owns 820,069 shares of the company's stock worth $4,568,000 after buying an additional 504,086 shares during the period. Norges Bank acquired a new stake in shares of 4D Molecular Therapeutics during the 4th quarter worth approximately $2,790,000. Wellington Management Group LLP grew its position in shares of 4D Molecular Therapeutics by 6.7% during the 4th quarter. Wellington Management Group LLP now owns 177,279 shares of the company's stock worth $987,000 after buying an additional 11,089 shares during the period. Finally, Peapod Lane Capital LLC acquired a new stake in shares of 4D Molecular Therapeutics during the 4th quarter worth approximately $806,000. Institutional investors own 99.27% of the company's stock.

4D Molecular Therapeutics Trading Down 3.3%

FDMT stock traded down $0.11 during midday trading on Tuesday, hitting $3.21. The company had a trading volume of 137,924 shares, compared to its average volume of 832,364. 4D Molecular Therapeutics, Inc. has a 52 week low of $2.24 and a 52 week high of $28.93. The stock's 50 day moving average price is $3.37 and its 200 day moving average price is $5.22. The stock has a market cap of $148.70 million, a price-to-earnings ratio of -1.13 and a beta of 2.87.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.02). Analysts predict that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current year.

Analyst Ratings Changes

FDMT has been the topic of a number of research reports. Barclays dropped their price target on 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating on the stock in a research note on Friday. HC Wainwright reissued a "buy" rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Monday, March 3rd. Leerink Partners dropped their price objective on 4D Molecular Therapeutics from $31.00 to $27.00 and set an "outperform" rating on the stock in a research note on Monday, January 13th. Weiss Ratings restated a "sell (e+)" rating on shares of 4D Molecular Therapeutics in a research note on Saturday. Finally, The Goldman Sachs Group dropped their price objective on 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating on the stock in a research note on Friday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $29.56.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.